{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:55:33Z","timestamp":1788990933216,"version":"build-2803163510"},"reference-count":47,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14702","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T12:08:56Z","timestamp":1727438936000},"source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of immune checkpoint inhibitors for colorectal cancer: A network meta\u2011analysis"],"prefix":"10.3892","volume":"28","author":[{"given":"Chih-Chen","family":"Tzang","sequence":"first","affiliation":[{"name":"School of Medicine, College of Medicine, National Taiwan University, Taipei 100, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Wei","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chen","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine, National Taiwan University, Taipei 100, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Huei","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Physical Therapy and Graduate Institute of Rehabilitation Science, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Fu","family":"Kang","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine, National Taiwan University, Taipei 100, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Lo\u2011Hsu Medical Foundation, Inc., Lotung Poh\u2011Ai Hospital, Yilan 265, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 100, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Vin","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 100, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"key20241112101826_b1-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20241112101826_b2-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/cancers14071732","article-title":"Colorectal cancer: A review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies","volume":"14","author":"Hossain","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20241112101826_b3-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.6027","article-title":"Diagnosis and treatment of metastatic colorectal cancer: A review","volume":"325","author":"Biller","year":"2021","journal-title":"JAMA"},{"key":"key20241112101826_b4-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"key20241112101826_b5-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00384-021-04028-z","article-title":"Efficacy and safety of immune checkpoint inhibitors in colorectal cancer: A systematic review and meta-analysis","volume":"37","author":"Zeng","year":"2022","journal-title":"Int J Colorectal Dis"},{"key":"key20241112101826_b6-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: Rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20241112101826_b7-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"key20241112101826_b8-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"key20241112101826_b9-ol-28-6-14702","article-title":"Chapter 11: Undertaking network meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.3","author":"Chaimani","year":"2024"},{"key":"key20241112101826_b10-ol-28-6-14702","article-title":"Chapter 10: Analysing data and undertaking meta-analyses","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4","author":"Deeks","year":"2023"},{"key":"key20241112101826_b11-ol-28-6-14702","article-title":"Chapter 23: Including variants on randomized trials","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5","author":"Higgins","year":"2024"},{"key":"key20241112101826_b12-ol-28-6-14702","article-title":"Chapter 13: Assessing risk of bias due to missing results in a synthesis","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5","author":"Page","year":"2024"},{"key":"key20241112101826_b13-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key20241112101826_b14-ol-28-6-14702","article-title":"Guidance for industry: Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials","author":"U.S. Food and Drug Administration","year":"2007"},{"key":"key20241112101826_b15-ol-28-6-14702","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/9780470743386.ch13","article-title":"Fixed-effect versus random-effects models","volume-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"key":"key20241112101826_b16-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jrsm.1373","article-title":"MetaInsight: An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and netmeta","volume":"10","author":"Owen","year":"2019","journal-title":"Res Synth Methods"},{"key":"key20241112101826_b17-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20241112101826_b18-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"key20241112101826_b19-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: The Canadian cancer trials group CO.26 study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20241112101826_b20-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"e002996","DOI":"10.1136\/jitc-2021-002996","article-title":"Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: The CARACAS study","volume":"9","author":"Lonardi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"key20241112101826_b21-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","article-title":"Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): A multicentre, open-label, randomised, controlled, phase 2 trial","volume":"23","author":"Antoniotti","year":"2022","journal-title":"Lancet Oncol"},{"key":"key20241112101826_b22-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/s41416-022-02004-0","article-title":"Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable\/mismatch repair-proficient metastatic colorectal cancer","volume":"127","author":"Meltzer","year":"2022","journal-title":"Br J Cancer"},{"key":"key20241112101826_b23-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/oncolo\/oyab046","article-title":"A randomized phase II trial of mFOLFOX6 + bevacizumab alone or with AdCEA vaccine + avelumab immunotherapy for untreated metastatic colorectal cancer","volume":"27","author":"Redman","year":"2022","journal-title":"Oncologist"},{"key":"key20241112101826_b24-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"100559","DOI":"10.1016\/j.esmoop.2022.100559","article-title":"MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer","volume":"7","author":"Tabernero","year":"2022","journal-title":"ESMO Open"},{"key":"key20241112101826_b25-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejca.2023.01.023","article-title":"Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer","volume":"184","author":"Ducreux","year":"2023","journal-title":"Eur J Cancer"},{"key":"key20241112101826_b26-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"e005640","DOI":"10.1136\/jitc-2022-005640","article-title":"Phase I\/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer","volume":"11","author":"Monge","year":"2023","journal-title":"J Immunother Cancer"},{"key":"key20241112101826_b27-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1001\/jamaoncol.2023.2761","article-title":"Avelumab vs standard second-line chemotherapy in patients with metastatic colorectal cancer and microsatellite instability: A randomized clinical trial","volume":"9","author":"Ta\u00efeb","year":"2023","journal-title":"JAMA Oncol"},{"key":"key20241112101826_b28-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"e2149040","DOI":"10.1001\/jamanetworkopen.2021.49040","article-title":"Assessment of capecitabine and bevacizumab with or without atezolizumab for the treatment of refractory metastatic colorectal cancer: A randomized clinical Trial","volume":"5","author":"Mettu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"key20241112101826_b29-ol-28-6-14702","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"key20241112101826_b30-ol-28-6-14702","first-page":"1764","article-title":"PD-L1 expression in colon cancer and its relationship with clinical prognosis","volume":"12","author":"Shan","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"key20241112101826_b31-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: Past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"key20241112101826_b32-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20241112101826_b33-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"key20241112101826_b34-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","article-title":"A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer","volume":"26","author":"Wu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20241112101826_b35-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"17562848211002018","DOI":"10.1177\/17562848211002018","article-title":"Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer","volume":"14","author":"Manz","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"key20241112101826_b36-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20241112101826_b37-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"key20241112101826_b38-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"key20241112101826_b39-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"S364","DOI":"10.21037\/tlcr.2019.06.06","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer","volume":"8","author":"Jove","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"key20241112101826_b40-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"e2340695","DOI":"10.1001\/jamanetworkopen.2023.40695","article-title":"Survival among veterans receiving steroids for immune-related adverse events after immune checkpoint inhibitor therapy","volume":"6","author":"Van Buren","year":"2023","journal-title":"JAMA Netw Open"},{"key":"key20241112101826_b41-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"e14692","DOI":"10.1200\/JCO.2023.41.16_suppl.e14692","article-title":"Do corticosteroids affect immunotherapy efficacy in malignancy? A systematic review","volume":"41","author":"Byron","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20241112101826_b42-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1084\/jem.20190738","article-title":"Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids","volume":"216","author":"Tokunaga","year":"2019","journal-title":"J Exp Med"},{"key":"key20241112101826_b43-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"e002261","DOI":"10.1136\/jitc-2020-002261","article-title":"Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer","volume":"9","author":"Maslov","year":"2021","journal-title":"J Immunother Cancer"},{"key":"key20241112101826_b44-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1002\/cam4.5085","article-title":"Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes","volume":"12","author":"Liu","year":"2023","journal-title":"Cancer Med"},{"key":"key20241112101826_b45-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"969447","DOI":"10.3389\/fimmu.2022.969447","article-title":"Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"key20241112101826_b46-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jhep.2016.10.029","article-title":"Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma","volume":"66","author":"Duffy","year":"2017","journal-title":"J Hepatol"},{"key":"key20241112101826_b47-ol-28-6-14702","doi-asserted-by":"publisher","first-page":"580241","DOI":"10.3389\/fonc.2020.580241","article-title":"Ablation reboots the response in advanced hepatocellular carcinoma with stable or atypical response during PD-1 therapy: A proof-of-concept study","volume":"10","author":"Lyu","year":"2020","journal-title":"Front Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T08:18:35Z","timestamp":1731399515000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":47,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,9,27]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14702","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"article-number":"569"}}